What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.
DUBLIN, Oct. 19, 2023 /PRNewswire/ — The “Medication Adherence Devices – A Global and Regional Analysis: Analysis and Forecast, 2023-2033” report has been added to ResearchAndMarkets.com’s offering. The Medication Adherence Market Report presents a comprehensive analysis of the…
NEW YORK, Oct. 19, 2023 /PRNewswire/ — The cell line development market size is expected to grow by USD 6.2 billion from 2022 to 2027. In addition, the growth momentum of the market will be progressing at a CAGR of 14.09% during the forecast period, according to Technavio Research. North…
ASHEVILLE, N.C., Oct. 19, 2023 /PRNewswire/ — The Centers for Disease Control reports, “Every second an adult in the U.S. falls.” Additional CDC research shows falls are the leading cause of injury and death in people over age 65. To help you be proactive in taking preventive measures,…
The IO360° 2024 keynotes include:
Genentech’s Ira Mellman, PhD, VP, Cancer Immunology, will speak on the roles of data mining and AI, and other clinical and translational data, in discovery and trial design.
Moffitt Cancer Center’s Patrick Hwu, MD, President and CEO, will speak about the work being done in immuno-oncology at one of the nation’s leading cancer hospitals.
University of California, San Francisco’s Laura Esserman, MD, MBA, Director of the UCSF Carol Franc Buck Breast Cancer Center, will share exclusive data on neoadjuvant strategies to assess immuno-oncology candidates.
Weill Cornell Medicine’s Taha Merghoub, PhD, Deputy Director, Sandra and Edward Meyer Cancer Center, will present the clinical evolution of the immuno-oncology field after PD-1.
Memorial Sloan Kettering Cancer Center’s Margaret Callahan, MD, PhD, Medical Oncologist and Immunotherapeutics Program Research Director, will give a historical perspective of tumor vaccines with an emphasis on optimism for the new class of RNA vaccines.
Citi’s Andrew Baum, MD, Managing Director, Equity Research, returns to provide the latest and most cutting-edge data on what is upcoming for the IO radar.
“The IO360º conference presents the latest data impacting the IO landscape and for the 10th annual event, we are pleased to announce the extraordinary leadership advancing this space. IO360º provides a gathering place for R&D representing both pharma and biotech with investors to navigate a complex landscape,” said Kate Woda, Director of IO360º.
The IO360° 2024 featured speakers include:
University of Pittsburgh Hillman Cancer Center’s Jason Luke, MD, FACP, Director, Immunotherapy and Drug Development Center, shares lessons learned in the past decade that could help to advance cancer immunotherapies.
Fidelity Investments’ Rajiv Kaul, Portfolio Manager, Equity Division, will provide his perspective on public investing in a difficult IPO market in a fireside chat with Scorpion Therapeutics’ CEO, Axel Hoos, MD, PhD.
Generate Bio’s Alexandra Snyder, MD, EVP, R&D, will discuss how generative AI could directly impact how IO drugs are developed.
VIP Patient Guest, Kelly Spill Bonito, will speak to the IO360º audience about the incredible immunotherapy trial that gave her back her life after a Stage III colorectal cancer diagnosis.
NYU Langone Medical Center’s Jeffrey Weber, MD, PhD, Deputy Director, Perlmutter Cancer Center, will present neoantigen cancer vaccine randomized Phase II data.
The key topic areas for 2024 cover:
To learn more about IO360, visit io360summit.com.
About Immuno-Oncology 360º:
IO360˚ is an annual conference in NYC that convenes key stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.
About the Conference Forum:
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. The company also publishes six newsletters and produces PharmaTalkRadio and virtual events.
Media Contact
Bre Bugbee, The Conference Forum, 1-646-350-2580, [email protected], http://www.io360summit.com/
SOURCE The Conference Forum
WASHINGTON, Oct. 19, 2023 /PRNewswire/ — Rebuilding Together, the leading national nonprofit organization providing critical home repairs and revitalizing our communities announced today a $9 million gift from philanthropist MacKenzie Scott. “The work of Rebuilding Together is unique in…
Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio discovers possible early signals of metastatic lung cancer, leading to an NCI grant and pending trials that could lead to new treatment.
SAN ANTONIO, Oct. 19, 2023 /PRNewswire-PRWeb/ — Researchers at Mays Cancer Center at The University of Texas Health Science at San Antonio (UT Health San Antonio) have identified protein markers that could signal for early development of metastatic lung cancer, providing possibilities for new treatment.
The findings already have led to a five-year, $1.6 million grant from the National Cancer Institute of the National Institutes of Health that will pave the way for a clinical trial next year for patients with advanced lung cancer. The research is detailed in a new article in Cell Reports, a peer-reviewed scientific journal publishing research papers across a broad range of disciplines within the life sciences.
“For the trial, we will be looking to recruit patients with lung adenocarcinoma, the most common primary lung cancer in the United States, and particularly those with a refractory condition for which treatment hasn’t been effective,” said Josephine A. Taverna, MD, a faculty member in hematology and oncology with Mays Cancer Center and principal investigator of the NCI/NIH grant.
She also is a lead author of the Cell Reports article titled, “AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages,” along with Tim Hui-Ming Huang, PhD, professor and chair of the Department of Molecular Medicine at UT Health San Antonio and deputy director of Mays Cancer Center.
They are joined by a team of clinical investigators at Mays Cancer Center and faculty in the departments of molecular medicine, cardiothoracic surgery, pulmonology, population health sciences and biostatistics at UT Health San Antonio, along with The University of Texas MD Anderson Cancer Center in Houston and industry partners BerGenBio and Sobi.
Tumor-associated macrophages are types of white blood cells that in dysfunctional form are integral to the development of complex tumor microenvironments, or ecosystems, promoting tumor growth, invasion, metastasis and drug resistance. Signaling of these macrophages early on for lung cancer has been elusive.
However, the research by Taverna and her colleagues indicates that certain proteins known as AXL and STAT3 together transmit signals that appear in more advanced stages of lung cancer. This signaling in tumor-associated macrophages is triggered by lung cancer cells and cancer-associated cells.
“These findings suggest the potential application of AXL-STAT3-related markers to quantitatively assess metastatic potential and inform therapeutic strategies in lung cancer,” Taverna said. “It provides a therapeutic rationale for targeting this network.”
The researchers derived their results by conducting single-cell proteomic profiling of 15 lung tumors from 13 patients with lung adenocarcinoma, one patient with squamous cell lung cancer and one patient with pleiomorphic carcinoma. They found predominant and consistent AXL-STAT3 signaling in tumor and other cancer-related cells.
“Our initial observation suggests that concomitantly high AXL/STAT3 signaling in tumor-associated macrophages may contribute to the conditioning of pro-metastatic niches,” Taverna said. “Our experiments in the lab suggest that targeting the AXL-STAT3 pathway can prevent tumor cells from recruiting tumor-associated macrophages and other aggressive host cells into the tumor microenvironment, thereby inhibiting tumor growth and spread.”
UT Health San Antonio is the largest academic research institution in South Texas with an annual research portfolio of more than $360 million.
AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages
Chia-Nung Hung, Meizhen Chen, Daniel T. DeArmond, Cheryl Hsiang-Ling Chiu, Catherine A. Limboy, Xi Tan, Meena Kusi, Chih-Wei Chou, Li-Ling Lin, Zhao Zhang, Chiou-Miin Wang, Chun-Liang Chen, Kohzoh Mitsuya, Pawel A. Osmulski, Maria E. Gaczynska, Nameer B. Kirma, Ratna K. Vadlamudi, Don L. Gibbons, Steve Warner, Andrew J. Brenner, Daruka Mahadevan, Joel E. Michalek, Tim Hui-Ming Huang, Josephine A. Taverna
First published: Sept. 1, 2023, Cell Reports
Link to the article: https://www.cell.com/cell-reports/fulltext/S2211-1247(23)01078-1
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is one of the country’s leading health science universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions, graduate biomedical sciences and public health have graduated more than 42,200 alumni who are leading change, advancing their fields and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit UTHealthSA.org.
Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.
The Mays Cancer Center at UT Health San Antonio is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. To learn more, visit https://cancer.uthscsa.edu.
Stay connected with the Mays Cancer Center on Facebook, Twitter, LinkedIn, Instagram and YouTube.
Media Contact
Steven Lee, The University of Texas Health Science Center at San Antonio, 210-450-3823, [email protected], news.uthscsa.edu
SOURCE The University of Texas Health Science Center at San Antonio
Key Highlights of Dr. Anil Shah’s Presentation:
Ultrasonic Rhinoplasty Revolution
Dr. Shah will delve into the principles and techniques that make ultrasonic rhinoplasty an industry game-changer. Attendees will gain a deep understanding of how this approach has redefined rhinoplasty, offering superior results and shorter recovery times.
Live Demonstrations
In a dynamic presentation, Dr. Shah will conduct live demonstrations of ultrasonic rhinoplasty techniques, showcasing the intricacies and precision of the procedure. This hands-on experience will allow attendees to witness firsthand the potential of this transformative approach.
Patient Case Studies
Dr. Shah will present a series of compelling patient case studies, highlighting the remarkable transformations achieved through ultrasonic rhinoplasty. These real-life examples will underscore the procedure’s ability to deliver natural, aesthetically pleasing results.
Advancements in Technology
Dr. Anil Shah is renowned for his commitment to staying at the forefront of technological advancements in plastic surgery. He will discuss the latest innovations and tools that have further refined the ultrasonic rhinoplasty procedure.
Dr. Anil Shah expressed his enthusiasm for the upcoming conference: “I am honored to be part of the Global Aesthetics Conference and share my passion for ultrasonic rhinoplasty with fellow surgeons and professionals from around the world. This innovative approach has the potential to transform patients’ lives, and I am excited to empower my colleagues with the knowledge and skills to achieve exceptional results.”
The Global Aesthetics Conference is a premier international event that provides a platform for medical professionals to exchange ideas, gain insights, and explore the latest advancements in aesthetics and plastic surgery. Dr. Anil Shah’s participation as a featured speaker underscores his position as a leading figure in the field.
For media inquiries, interviews, or additional information about Dr. Anil Shah’s presentation at the Global Aesthetics Conference, please contact:
Dr. Anil Shah, Shah Facial Plastics
200 West Superior Street, Suite 200
Chicago, IL 60654
312.944.0117
About Dr. Anil Shah:
Dr. Anil Shah is a globally renowned plastic surgeon and a pioneer in the field of ultrasonic rhinoplasty. With a commitment to precision, innovation, and patient-centric care, he has consistently delivered exceptional results to patients worldwide. Dr. Shah’s expertise has earned him recognition as a leading authority in the field of plastic surgery.
Website: https://www.shahfacialplastics.com/
Social Media:
IG: https://www.instagram.com/shahaesthetics/
TikTok: https://www.tiktok.com/@shahaesthetics
Media Contact
Emily Simarski, RAGDOLL PR, 1 4144912914, info@ragdollpr.com
SOURCE Dr. Anil Shah
MYOS CORP, an innovation-driven nutrition company, proudly unveils insights surrounding its signature muscle health ingredient, Fortetropin®. Preliminary observations by esteemed experts suggest that Fortetropin might be a promising solution to the muscle deterioration linked with certain mainstream weight loss products.
Dr. William Evans, a distinguished scholar at both the University of California-Berkeley and Duke University, is an internationally recognized expert in muscle science research. His group’s 2020 publication illuminated Fortetropin’s potential, demonstrating how this singular proteo-lipid compound resulted in a substantial, 18% elevation in the rate of muscle protein synthesis in older adults. Notably, this enhancement occurred without any increase in physical activity on the part of the subjects, suggesting that Fortetropin has inherent anabolic properties, even for largely inactive individuals.
“Fortetropin has a robust effect on the rate of muscle protein synthesis in older men and women. It is rare for a nutrition product to show such a consistent and positive effect,” Evans said of the results.
The results of the 2020 study provide implications for the challenge of preserving muscle mass during treatment with new weight loss products, as the adoption of such drugs has skyrocketed across the country that is still relevant today. Use of products containing GLP-1 agonists (such as semaglutide) result in weight loss resulting from reduced appetite and decreased food intake. However, like many weight loss products, it can lead to muscle loss.
By combining a muscle health product like Fortetropin with a weight loss product, users should enjoy the weight loss benefits without the same degree of muscle depletion. It’s like having the best of both worlds—shedding excess weight without sacrificing hard-earned muscle. Although direct evidence linking Fortetropin’s efficacy in counteracting muscle loss from weight loss products is currently lacking, experts such as Dr. Evans considers it a compelling avenue warranting deeper exploration.
“Stimulation of muscle protein synthesis, which Fortetropin has shown it provides, can have a positive effect of preserving muscle mass and increasing fat loss,” said William Evans. “The loss of muscle mass is common when individuals, especially as we age, lose weight rapidly.”
Embracing this potential, MYOS envisions a synergistic approach, contemplating the pairing of Fortetropin with weight loss treatments. This could create an optimal balance, allowing individuals to reduce excess weight without compromising their precious lean muscle mass.
“Fortetropin’s distinct advantage in our Yolked line is its power to boost muscle growth and reduce muscle loss, all with a mere 60 calories per serving. It’s an ideal choice for those aiming to shed weight without compromising muscle integrity,” remarked MYOS CORP CEO Joe Mannello. “Metabolism is your body’s mechanism of transforming intake into energy. A robust muscle mass increases your metabolic rate. However, when weight and muscle decrease, your metabolism decelerates, hindering your weight loss progress.”
In addition to the aforementioned study at Cal Berkeley, there have been eight successful studies of Fortetropin showing its positive effect on muscle health. Among these, two highlighted clinical trials stand out:
“Our Yolked brand has garnered immense respect among athletes in the sports nutrition domain. Now, we’re poised to address the muscle health of those striving to lose weight, ensuring they retain or even increase their muscle throughout the process,” said Mannello.
About MYOS CORP
MYOS CORP is a Cedar Knolls, NJ-based medical nutrition company that develops products that improve muscle health in people and animals. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass, and reduce muscle atrophy. For more information, please visit www.myoscorp.com.
Media Contact
Cynthia Sutherland, MYOS CORP, 1 (212) 597-2259, [email protected], https://yolked.com
SOURCE MYOS CORP
Certification Underscores HumanSignal’s Commitment to Data Security and Privacy for Healthcare Data Labeling
SAN FRANCISCO, Oct. 19, 2023 /PRNewswire-PRWeb/ — HumanSignal is proud to announce the successful attainment of HIPAA (Health Insurance Portability and Accountability Act) compliance for its flagship data labeling platform, Label Studio Enterprise. HIPAA compliance is a significant milestone for HumanSignal, demonstrating the company’s dedication to safeguarding sensitive healthcare data, and enabling healthcare organizations to take advantage of its cloud-based platform without the need to manage on-prem infrastructure.
Healthcare organizations are applying machine learning and AI in many innovative ways, from accelerating research to improving patient care, which makes high quality, secure data labeling a critical part of the pipeline. This certification validates that Label Studio Enterprise adheres to the strict regulatory requirements set forth by HIPAA, ensuring the confidentiality, integrity, and availability of protected health information (PHI). Key benefits of Label Studio Enterprise achieving HIPAA compliance include:
“We are thrilled to announce our achievement of HIPAA compliance for Label Studio Enterprise,” said Michael Malyuk, CEO at HumanSignal. “This certification reflects our unwavering commitment to ensuring the highest standards of data security and privacy for healthcare applications. With the healthcare sector increasingly adopting machine learning and AI, we are proud to offer data labeling platform that enables efficiency, accuracy and data privacy.”
To learn more about how Label Studio Enterprise is architected to protect sensitive healthcare data, read our latest blog.
About HumanSignal
HumanSignal enables data science teams to build AI models with their company DNA. With the emergence of generative AI, it’s more important than ever to build and tune differentiated models with proprietary data and human feedback. Creators of the most popular open source data labeling platform, Label Studio, HumanSignal enables data scientists to develop high quality datasets and workflows for model training, fine tuning, and continuous validation.
Today, the Label Studio open source community has more than 250,000 users who have collectively annotated more than 100 million pieces of data. Label Studio Enterprise is available as a cloud service with enhanced security, automation, quality review workflows, and performance reporting, used by leading data science teams including Geberit, Lufthansa, Outreach, Wyze, and Zendesk. For more information, visit humansignal.com.
Media Contact
Lauren Sell, HumanSignal, 1 415-996-0806, [email protected], https://www.humansignal.com
SOURCE HumanSignal
SMC National educates, trains and supports dental practices of all sizes with its comprehensive patient acquisition marketing solutions that are custom-built for today’s market. By bringing more patients into practices, the company reduces the significant time typically spent on patient recruitment, allowing dental leaders to better focus on their clinical and financial objectives. However, it is also critically important that those patients are able to agree to necessary care.
When it comes to improving treatment plan acceptance and production, Sunbit outperforms. The company’s technology offers lightning-fast access to personalized financing options to virtually every patient, and everyone who is approved is offered fair, transparent, and fee-free choices. In three years, Sunbit has enabled 400,000 patients to access patient financing, with more than $560 million in production generated across the industry.
“Partnerships are critically important to us, helping us to reach more patients, faster,” said Robert Nunziato, Head of Strategic Alliances, Sunbit. “SMC is an exciting force in dentistry, with an approach that is as effective as it is creative. SMC National’s customers are already seeing incredible results, and we’re thrilled to be a part of their future.”
About SMC National:
SMC National generates new revenue for growth-minded dentists and dental group leaders. A three-time INC 5000 company, we partner with hundreds of practices to create new patients, improve conversion and case acceptance, and build lasting patient loyalty. Learn more at smcnational.com.
About Sunbit:
Sunbit builds financial technology for real life. Our technology eases the stress of paying for life’s expenses by giving people more options on how and when they pay. Sunbit offers a next-generation, no-fee credit card that can be managed through a powerful mobile app, as well as a point-of-sale payment option available at more than 20,000 service locations, including auto dealership service centers, optical practices, dentist offices, veterinary clinics, and specialty healthcare services. Sunbit is a two-time Inc. 5000 honoree. The financial technology company has also been named a Most Loved Workplace®, Best Point of Sale Company, a Deloitte Technology Fast 500 company and a Top Fintech Startup by CB Insights. Loans are made by Transportation Alliance Bank, Inc., dba TAB Bank, which determines qualifications for and terms of credit. The Sunbit Card is issued by TAB Bank, pursuant to a license from Visa U.S.A. Inc. Use of the card is subject to the cardholder agreement.
Media Contact
Sunbit, Sunbit, 8133002905, [email protected], www.sunbit.com
SOURCE Sunbit
